Short answer
Alamar Biosciences Inc (ALMR) filed an 8-K current report with the SEC on August 10, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
Alamar Biosciences Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release Exhibit 99.1 contains the reported financial figures and management commentary
- Results announcement provides investors the company’s latest quarterly performance update
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 revenue $29.4M, up 82% year over year, led by consumables revenue growth of 147% to $15.5M
- Gross margin improved to 60% from 53%, reflecting manufacturing efficiencies and higher-margin consumables mix
- Operating expenses rose 89% to $31.2M, driving operating loss of $13.5M versus $7.9M
- Cash, investments and restricted cash totaled $256.3M at June 30, 2026, supporting continued investments in growth and R&D
- 2026 revenue guidance $116M to $120M, representing 59% midpoint growth, with eMTBR-tau and Immune 340 launches expanding the platform menu
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alamar Biosciences Inc 8-K filings
Get the next ALMR 8-K as it lands
Follow ALMR for push alerts, or ask the research agent what this filing means.